However, while NPM1-mutated AML in younger adults is generally associated with favorable clinical outcomes, especially in the absence of FLT3-ITD, in older patients the risk of relapse is markedly higher (1-year CIR 71% in patients aged >65 years) and survival significantly lower (2-year OS 19%) [88]. Here, FLT3 is linked to acute myeloid leukemia.